CCHT(SZ:000661) Xin Lang Cai Jing·2026-02-25 07:31Group 1 - The core viewpoint of the news is that Changchun High-tech (SZ000661) experienced a significant stock price increase, reaching a limit up of 97.26 yuan, with a rise of 9.98% and a total market capitalization of 39.668 billion yuan [1] - The reasons for the stock surge are attributed to the company's strong focus on innovative drug development, technology licensing, and international expansion, particularly through its subsidiary, Jinsai Pharmaceutical, which has made notable progress in various therapeutic areas [2] - Changchun High-tech has 15 Class 1 new drug projects at different stages of development, showcasing its robust research capabilities and aligning with the industry's trend of high market interest in companies with rich innovative drug pipelines [2] Group 2 - The company secured a $120 million upfront payment and potential milestone payments of $1.365 billion through the GenSci098 project technology licensing, laying a solid foundation for long-term growth [2] - The pharmaceutical industry is currently highly focused on innovative drug development, and companies that engage in international cooperation are favored by the market, which aligns with Changchun High-tech's strategy [2] - Technical analysis indicates that positive signals, such as the MACD indicator forming a golden cross, could enhance market confidence and attract further investment, potentially leading to continued stock price increases [2]